Aditya Bharadwaj is a Cardiology physician. OpenAlex indexes 130 publications with 1,714 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11234 Anderson St Spc 1617
Loma Linda, CA 923542804
Telephone
909-558-4200Provider last certified this registry record 2 Apr 2025.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABIOMEDProgram year202514 payments$14,400openpaymentsdata.cms.gov ↗
- Medtronic, Inc.Program year20252 payments
- Abbott LaboratoriesProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
75.3%Beta blocker22.4%Metoprolol Succinate43%Carvedilol35%Metoprolol Tartrate22%Part D≥33 patientsStatin12.3%Atorvastatin Calcium69%Rosuvastatin Calcium31%Part D≥31 patients+ 10 more classes in this area
Blood & clotting
19.9%P2Y12 inhibitor12%Clopidogrel68%Brilinta32%Part D≥33 patientsFactor Xa inhibitor7.9%Eliquis75%Xarelto25%Part D<11 patientsMetabolism & gastrointestinal
4.8%SGLT2 inhibitor3.4%Farxiga100%Part D<11 patientsPotassium supplement1.4%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Novel risk score for patients undergoing Impella-assisted high-risk percutaneous coronary intervention
Cardiovascular revascularization medicine
2025 - Outcomes With Limus- vs Paclitaxel-Coated Balloons for Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions
2024 - Characteristics of Patients Undergoing High-Risk Percutaneous Coronary Intervention in Contemporary United States Practice
The American Journal of Cardiology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”